Covid-19 and drug therapy, what we learned

Provenzani, A; Polidori, Piera

doi:10.1007/s11096-020-01049-6

Cited by 16 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly true for the lab testing capacity, which has increased since the beginning of the pandemic, 29 and the list of drugs included because the therapeutic guidelines and protocols for patients with SARS-CoV-2 have extensively changed over time. 30 …”

Section: Discussionmentioning

confidence: 99%

The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective To create an informatics supportive tool, which can assist healthcare professionals in estimating potential requirements for essential drug supplies to respond to the current SARS-CoV-2 pandemic based on epidemiological forecasting. Methods The tool was based on a Susceptible-Infected-Removed (SIR) epidemiological model in which the population is divided into three compartments and transmission parameters are specified to define the rate at which people move between stages. Appropriate data entry was guaranteed by the creation of structured guided paths. The drugs needed for the forecasted patients were estimated according to a list of critical care drugs compiled by consulting previous published scientific works, national and international guidelines. For each drug, an estimation was made of the percentage average ICU uptake for each therapeutic group and active principle. Results The tool consists of a Microsoft Excel template that is based on the initial epidemiological situation, the non-pharmaceutical interventions applied, the risk of hospitalisation based on the population age distribution, and the hospital beds available. The tool provides a forecast of which patients with COVID-19 will need to be treated in a hospital setting. The number of patients is used to estimate the drugs needed based on the average daily dose and the treatment length of each drug. The possibility of editing the type of distribution (exponential or linear) of the number of patients at the beginning of the analysis, the percentage adherence with non-pharmaceutical interventions and their delayed effect, and all the key epidemiological parameters make the estimation tailorable to different clinical contexts and needs. Conclusions This model might be an effective supporting tool that could be easily implemented within the workflow of health professionals. All the information reported in this paper could be useful in developing new strategies to tackle the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In general, the pharmacological treatment in nonhospital settings is not recommended, as well as for young, healthy patients with mild symptoms, and without comorbidities 50 . Through the clinical treatment of the COVID‐19, it has been found that neuraminidase inhibitors (such as oseltamivir, peramivir, and zanamivir) are not sufficient, as this viral enzyme is not produced by coronaviruses.…”

Section: Treatments That Are Not Recommendedmentioning

confidence: 99%

“…Although SARS‐CoV‐2 infection is associated with a cytokine storm triggered by overactivation of the immune system, the corticosteroids treatment was not initially recommended for viral pneumonia, only for patients with refractory shock or acute respiratory distress syndrome 18,49–51 . Currently, a systematic living review and network meta‐analysis with data from eight randomized trials (7184 participants) made a strong recommendation for use of corticosteroids in severe and critical COVID‐19 because there is a lower risk of death among people treated with systemic corticosteroids (moderate certainty evidence).…”

Section: Treatments That Are Not Recommendedmentioning

confidence: 99%

SARS‐CoV‐2 virus infection: Targets and antiviral pharmacological strategies

Campos

Fulco

Oliveira³

et al. 2020

J Evidence Based Medicine

View full text Add to dashboard Cite

The current pandemic of coronavirus disease 2019 (COVID‐19), transmitted person‐to‐person by severe acute respiratory syndrome of coronavirus 2 (SARS‐CoV‐2), poses a threat to global public health. To present, these are still no clinically approved antibodies or drugs specific for SARS‐CoV‐2, which makes it difficult for controlling the associated pandemic, limited to monitoring and containment. This situation generates a new need for the development of safe and effective treatments. Since SARS‐CoV‐2 shares phylogenetic traits with SARS‐CoV and MERS‐CoV, antiviral medicines may provide some insight into the development of COVID‐19 therapeutics. Besides that, they are being prioritized several FDA‐approved drugs due to the pandemic state. Despite recent advances in the control of the current COVID‐19 pandemic, challenges such as the rapid virus spread and the socioeconomic cost of this outbreak remain for the inexistence of therapeutics agents against SARS‐CoV‐2. From this moment, the in vivo evaluation of FDA‐approved drugs, which until then appears to be effective are recommended, such as chloroquine, hydroxychloroquine, remdesivir, favipiravir, nitazoxanide, and ivermectin; besides new targets: Mpro, spike glycoprotein, and TMPRSS2 inhibitors. Therefore, these investigations are needed to prove the efficacy and safety of these potential candidates, including their side effects.

show abstract

“…Coronavirus infection COVID-19 (abbreviation for the English COronaVIrus Disease 2019) is a potentially severe critical respiratory infection caused by the coronavirus SARS-CoV-2 (2019-nCoV) [2], a dangerous disease that can occur in the form of an acute respiratory viral infection of the lung [3].…”

Section: Introductionmentioning

confidence: 99%

University life during pandemic COVID-19: Attitudes of staff and students towards distance education

2021

View full text Add to dashboard Cite

Research background: The analysis of the problem was carried out according to the standard scheme: collection of information - description of the received data - generalization of data - recommendations. All the information available on this subject was obtained by questioning teachers, administrative staff and students. Purpose of the article: This case study is aimed at studying social objects and relationships in the process of transition from traditional to remote education methods to obtain new information and identify relevant patterns that depend on gender and position at the university. Methods: An online survey was conducted among 1792 people from March 15 to April 15, 2020 through an electronic questionnaire. The sample included academic and administrative staff, and UNEC’s students. Using the SPSS statistical software package, the Chi Square test is calculated. Findings & Value added: The advantage of this study is the creation of a model that can be used not only to interpret the results of a sociological survey in real time, but also to make decisions and develop strategies for future developments.

show abstract

Covid-19 and drug therapy, what we learned

Cited by 16 publications

References 30 publications

The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic

The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic

SARS‐CoV‐2 virus infection: Targets and antiviral pharmacological strategies

University life during pandemic COVID-19: Attitudes of staff and students towards distance education

Contact Info

Product

Resources

About